Kintor Pharma of Suzhou started a global Phase III trial of proxalutamide in hospitalized COVID-19 patients. Kintor said its candidate is the only small-molecule oral drug that has started a Phase III MRCT trial for hospitalized COVID-19 patients. The primary endpoint for the trial is the time to sustained recovery evaluated by Day 30, with a secondary endpoint of 30-day mortality. The pivotal study has been approved by the US, China, Philippines and ANVISA, and it is seeking for approval by more regulatory agencies in Europe and  Asia . More details.... Stock Symbol: (HK: 9939) Share this with colleagues: // //